BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 16026743)

  • 1. Myeloma bone disease.
    Berenson JR
    Best Pract Res Clin Haematol; 2005; 18(4):653-72. PubMed ID: 16026743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment for myeloma bone disease.
    Yeh HS; Berenson JR
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6279s-6284s. PubMed ID: 17062714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloma bone disease and treatment options.
    Yeh HS; Berenson JR
    Eur J Cancer; 2006 Jul; 42(11):1554-63. PubMed ID: 16797971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
    Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC
    Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
    Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs MJ; Blacklock HA; Bell R; Simeone J; Reitsma DJ; Heffernan M; Seaman J; Knight RD
    N Engl J Med; 1996 Feb; 334(8):488-93. PubMed ID: 8559201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
    Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
    Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
    Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
    Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic options in the management of myeloma bone disease.
    Berenson JR
    Semin Oncol; 2010 Jun; 37 Suppl 1():S20-9. PubMed ID: 20682368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone disease in myeloma.
    Berenson JR
    Curr Treat Options Oncol; 2001 Jun; 2(3):271-83. PubMed ID: 12057127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the biology and treatment of bone disease in multiple myeloma.
    Raje N; Roodman GD
    Clin Cancer Res; 2011 Mar; 17(6):1278-86. PubMed ID: 21411443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloma--the therapeutic challenge.
    Berenson JR
    Med Klin (Munich); 2000 Oct; 95 Suppl 2():19-21. PubMed ID: 11089383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis and management of myeloma bone disease.
    Christoulas D; Terpos E; Dimopoulos MA
    Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.
    Smith MR
    Cancer Treat Rev; 2005; 31 Suppl 3():19-25. PubMed ID: 16229955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of bone disease in multiple myeloma.
    Terpos E; Berenson J; Raje N; Roodman GD
    Expert Rev Hematol; 2014 Feb; 7(1):113-25. PubMed ID: 24433088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates in multiple myeloma.
    Berenson JR
    Cancer; 1997 Oct; 80(8 Suppl):1661-7. PubMed ID: 9362433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
    Musto P; Petrucci MT; Bringhen S; Guglielmelli T; Caravita T; Bongarzoni V; Andriani A; D'Arena G; Balleari E; Pietrantuono G; Boccadoro M; Palumbo A;
    Cancer; 2008 Oct; 113(7):1588-95. PubMed ID: 18683218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of multiple myeloma-related bone disease].
    Jurczyszyn A; Grosicki S; Czerniuk MR; Morga R; Małecki K; Skotnicki AB
    Przegl Lek; 2013; 70(11):950-7. PubMed ID: 24697037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone markers in multiple myeloma.
    Heider U; Fleissner C; Zavrski I; Kaiser M; Hecht M; Jakob C; Sezer O
    Eur J Cancer; 2006 Jul; 42(11):1544-53. PubMed ID: 16765040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in imaging and the management of myeloma bone disease.
    Terpos E; Moulopoulos LA; Dimopoulos MA
    J Clin Oncol; 2011 May; 29(14):1907-15. PubMed ID: 21483016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.